Ronald Silver - 28 Feb 2022 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
Principal Accounting Officer
Signature
/s/ Brian Tessler, Attorney-in-Fact
Issuer symbol
IRWD
Transactions as of
28 Feb 2022
Net transactions value
-$24,103
Form type
4
Filing time
02 Mar 2022, 15:01:58 UTC
Previous filing
24 Nov 2021
Next filing
04 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Sale $4,825 -448 -0.71% $10.77 63,001 28 Feb 2022 Direct F1, F2
transaction IRWD Class A Common Stock Sale $6,893 -640 -1% $10.77 62,361 28 Feb 2022 Direct F3
transaction IRWD Class A Common Stock Sale $12,386 -1,150 -1.8% $10.77 61,211 28 Feb 2022 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.
F2 The reporting person acquired 2,236 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2021.
F3 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2020.
F4 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 23, 2021.